Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.
Sacituzumab Earns Regular FDA Approval For TNBC NCI
Sacituzumab Earns Regular FDA Approval For TNBC NCI
.jpg)
New FDA Alert Warns of Drug Combination for Advanced Triple-Negative Breast Cancer Patients
Biomolecules, Free Full-Text
Trodelvy for the Treatment of Advanced Triple-Negative Breast Cancer
ASCO Experts Update Guidance for Sacituzumab Govitecan (Trodelvy
Sacituzumab govitecan in previously treated hormone receptor
Sacituzumab Govitecan - an overview
Michael Weingarten (@NCISBIRdirector) / X
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic
Three Treatment Modalities Emerge for Patients with Triple
Recent advances in targeted strategies for triple-negative breast cancer, Journal of Hematology & Oncology
FDA Approves Sacituzumab Govitecan for Triple-Negative Breast
Recent advances in targeted strategies for triple-negative breast cancer, Journal of Hematology & Oncology
Recent advances in targeted strategies for triple-negative breast
/cdn.vox-cdn.com/uploads/chorus_image/image/59342725/D76E413A_DF64_4280_8491_00E6C134D427.156.jpeg)
)
